EMA MR Draft Guidelines Application [Regulatives / Guidelines]

posted by Jay – India, 2013-12-23 12:00 (4565 d 20:52 ago) – Posting: # 12095
Views: 3,351

Dear John and Helmut,

Thank you for your reply.

❝ Why not? The problems start with the truncation time point (which has to be prespecified). I guess I will not have been the only one objecting against τ/2. The first pAUC might be highly variable (though widening of the acceptance range might be possible if the study was performed in a replicate design). If in doubt, go for a scientific advice.


Any idea about which truncation point to be considered for pAUC?

As pAUC is considered to be more variable as compared to Cmax and AUC. Thus should Sample Size be considered accourdingly? And if it is to be considered more subjects may be required. And for pAUC which literature should we consider for calculation of Sample Size?

Regards,
Jay

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
116 visitors (0 registered, 116 guests [including 12 identified bots]).
Forum time: 09:53 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5